Schneider LS, Psychopharmacol Bull 29:501-24 (1993).* |
Haan et al, Dementia 5:210-3 (1994).* |
U.S. patent application Ser. No. 07/920,933, Black et al., filed Jul. 28, 1992. |
U.S. patent application Ser. No. 07/995,222, Black et al., filed Dec. 22, 1992. |
U.S. patent application Ser. No. 08/035,121, Black et al., filed Mar. 19, 1993. |
U.S. patent application Ser. No. 08/082,218, Cullinan, filed Jun. 24, 1993. |
U.S. patent application Ser. No. 08/096,480, Hock, filed Jul. 22, 1993. |
U.S. patent application Ser. No. 08/112,012, Dodge et al., filed Aug. 15, 1993. |
U.S. patent application Ser. No. 08/111,796, Dodge et al., filed Aug. 25, 1993. |
U.S. patent application Ser. No. 08/081,610, Yang, filed Jun. 21, 1993. |
Draper et al., “Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women”, Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993. |
Bryant et al., “Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993. |
Bryant et al., “Raloxifene is a Tissue Specific Estrogen Agonist”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993. |
Frolick et al., “In Vivo and In Vitro Metabolism of Raloxifene”, Am. Soc. Bone & Res., Tampa, Sep. 18-22, 1993. |
Glasebrook et al., “Multiple Binding Sites for the Anti-estrogen Raloxifene”, Am Soc. Bone & Tampa, Sep. 18-22, 1993. |
Hock et al., “Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats”, Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993. |
Sato et al., “DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats”, Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993. |
Yang et al., “Raloxifene on Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through TGFB-3 Expression in Bone;”.Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993. |
Black et al., “Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;” The Endocrine Soceity, Abstract 1982. |
Black et al., “Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice,” Life Sciences, 26:1980, 1453-1458. |
Black et al., “Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors,” Molecular Endocrinology, 22:1981, 95-103. |
Black et al., “Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms,” Endocrinology 109;1981, 987-989. |
Black, L.J. “Biological Actions and Binding Properties of a New Estrogen Antagosist LY117018,” In: Homone Antagonists, 129-82, 1982 (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York. |
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982. |
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93. |
Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036. |
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323. |
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl) ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966. |
Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066. |
“Women on estrogen appear at less risk of Alzheimer's”, Indianapolis Star, p. 1, col. 1, Nov. 10, 1993. |